Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Behav Res Methods ; 48(2): 614-20, 2016 06.
Artigo em Inglês | MEDLINE | ID: mdl-26092392

RESUMO

We have constructed and tested a custom-made magnetic-imaging-compatible visual projection system designed to project on a very wide visual field (~80°). A standard projector was modified with a coupling lens, projecting images into the termination of an image fiber. The other termination of the fiber was placed in the 3-T scanner room with a projection lens, which projected the images relayed by the fiber onto a screen over the head coil, viewed by a participant wearing magnifying goggles. To validate the system, wide-field stimuli were presented in order to identify retinotopic visual areas. The results showed that this low-cost and versatile optical system may be a valuable tool to map visual areas in the brain that process peripheral receptive fields.


Assuntos
Imageamento por Ressonância Magnética/instrumentação , Imageamento por Ressonância Magnética/métodos , Estimulação Luminosa/instrumentação , Estimulação Luminosa/métodos , Adulto , Mapeamento Encefálico , Feminino , Humanos , Processamento de Imagem Assistida por Computador , Imageamento por Ressonância Magnética/economia , Masculino , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Campos Visuais
2.
Reprod Biomed Online ; 22 Suppl 1: S67-72, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21575852

RESUMO

The aim of this observational preliminary trial was to estimate the association between the most common polymorphism of LH (LH-ß variant: v-ßLH), with different profiles of ovarian response to recombinant human FSH (rhFSH). A total of 60 normogonadotrophic patients undergoing a gonadotrophin-releasing hormone analogue long down-regulation protocol followed by stimulation with recombinant human FSH (rhFSH) for IVF/intracytoplasmic sperm injection, and in whom at least five oocytes were retrieved were retrospectively included. On the basis of the total rhFSH consumption, patients were divided into three groups: Group A: 22 women requiring a cumulative dose of rhFSH >3500 IU; Group B: 15 patients requiring 2000-3500 IU; Group C (control): 23 women requiring <2000 IU. The presence of v-ßLH was evaluated using specific immunoassays. Peak oestradiol concentrations were significantly lower in Group A when compared with both groups B (P < 0.05) and C (P < 0.001). Group A had a significantly lower (P < 0.05) number of oocytes retrieved (7.3 ± 1.5, 11.7 ± 2.4 and 14.7 ± 4.1 in the three groups, respectively). Seven carriers (31.8%) of v-ßLH were found in Group A, whereas only one variant (6.7%) was observed in Group B; no variant was detected in Group C. These preliminary results suggest that v-ßLH is more frequent in women with ovarian resistance to rhFSH.

4.
Reprod Biomed Online ; 18(1): 9-14, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19146763

RESUMO

The aim of this observational preliminary trial was to estimate the association between the most common polymorphism of LH (LH-beta variant: v-betaLH), with different profiles of ovarian response to recombinant human FSH (rhFSH). A total of 60 normogonadotrophic patients undergoing a gonadotrophin-releasing hormone analogue long down-regulation protocol followed by stimulation with recombinant human FSH (rhFSH) for IVF/intracytoplasmic sperm injection, and in whom at least five oocytes were retrieved were retrospectively included. On the basis of the total rhFSH consumption, patients were divided into three groups: Group A: 22 women requiring a cumulative dose of rhFSH >3500 IU; Group B: 15 patients requiring 2000-3500 IU; Group C (control): 23 women requiring <2000 IU. The presence of v-betaLH was evaluated using specific immunoassays. Peak oestradiol concentrations were significantly lower in Group A when compared with both groups B (P < 0.05) and C (P < 0.001). Group A had a significantly lower (P < 0.05) number of oocytes retrieved (7.3 +/- 1.5, 11.7 +/- 2.4 and 14.7 +/- 4.1 in the three groups, respectively). Seven carriers (31.8%) of v-betaLH were found in Group A, whereas only one variant (6.7%) was observed in Group B; no variant was detected in Group C. These preliminary results suggest that v-betaLH is more frequent in women with ovarian resistance to rhFSH.


Assuntos
Resistência a Medicamentos/genética , Hormônio Liberador de Gonadotropina/análogos & derivados , Hormônio Luteinizante/genética , Indução da Ovulação/métodos , Polimorfismo de Nucleotídeo Único/fisiologia , Adulto , Substituição de Aminoácidos/fisiologia , Ensaios Clínicos como Assunto , Estradiol/sangue , Feminino , Fertilização in vitro/métodos , Frequência do Gene , Hormônio Liberador de Gonadotropina/uso terapêutico , Humanos , Ovulação/sangue , Ovulação/genética , Gravidez , Proteínas Recombinantes/uso terapêutico , Estudos Retrospectivos , Adulto Jovem
5.
Clin Ter ; 147(1-2): 3-7, 1996.
Artigo em Italiano | MEDLINE | ID: mdl-8767950

RESUMO

We have observed a deep venous thrombosis with pulmonary embolism in a young woman receiving low-dose oral contraceptives; this adverse drug effect was not associated with some risk factor and, in particular, with a demonstrable congenital or acquired clotting abnormality. It is reported that EP can induce deep venous thrombosis with different mechanisms, as hemorheological changes with subsequent poor clearance of locally activated clotting factors, or an increase of platelet or leukocytes aggregation, or a direct effect on some clotting factor; furthermore, it is well known that oral contraceptives may induce antibodies to synthetic hormones, with detection of circulating immune complexes, that might produce thrombosis by damaging the vascular endothelium or interfering with clotting factors or platelet aggregation. Moreover, only a familial history of thrombosis or a past history of recurrent deep venous thrombosis, especially in young age, may justify a broad and highly expensive screening of latent clotting abnormalities, that may significantly increase the risk of vascular thrombosis with the use of oral contraceptives.


Assuntos
Anticoncepcionais Orais Combinados/efeitos adversos , Embolia Pulmonar/induzido quimicamente , Adulto , Anticoagulantes/uso terapêutico , Feminino , Heparina/uso terapêutico , Humanos , Embolia Pulmonar/diagnóstico por imagem , Embolia Pulmonar/tratamento farmacológico , Cintilografia , Tromboflebite/induzido quimicamente , Tromboflebite/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...